Saniona Sets Goals for its Clinical Program of Tesomet for PWS
Saniona will continue to develop Tesomet (tesofensine/metoprolol) as a potential therapy for Prader-Willi syndrome (PWS), with results from a Phase 2a clinical study expected to be reported soon. The company has completed a rights issue in which it sold some of Saniona’s shares, resulting in gross revenue of SEK…